There are three common forms of APOE – e2, e3 and e4, all distinct alleles that have varying risks of Alzheimer's Disease (AD). At one end of the spectrum is e2, which reduces risk of developing ...

Revvity, Inc. RVTY announced the launch of the in-vitro diagnostic EURORealTime APOE assay in European countries that accept the CE mark on Oct. 2. The assay will likely enable accurate genotyping ...

The APOE gene has long been known to affect the risk of Alzheimer’s disease through its three main variants: E2 (low risk), E3 (intermediate risk), and E4 (high risk). More recently, a genetic ...

APOE ferries cholesterol throughout the body and brain and is thought to play a role in depositing or sweeping away sticky beta amyloid plaques, which are one hallmark of Alzheimer’s.

Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...